Residual, regrowth, and new growth of radiofrequency ablation for benign thyroid nodules of different volumes: two-year follow-up results

Chen, Meng‐Hsiang; Lin, Wei-Che; Luo, Sheng‐Dean; Chiang, Pi-Ling; Chen, Yueh-Sheng; Chen, Wei-Chih; Lin, An-Ni; Wang, Cheng-Kang; Baek, Jung Hwan; Chen, Hsiu-Ling

doi:10.1080/02656736.2022.2112305

Cited by 10 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The volume reduction rate (VRR) was used to determine the extent of shrinkage of the ablated nodule ( 19 ) and was evaluated by US at each follow-up point. Regrowth of ablated dominant nodules was defined as the volume of the ablated nodules increasing by ≥50% compared to the minimum recorded volume measured during the follow-up ( 20 , 21 ).…”

Section: Methodsmentioning

confidence: 99%

Two-year prognosis of multinodular goiter following radiofrequency ablation based on all nodule burdens

Guo,

Zheng,

et al. 2024

European Thyroid Journal

View full text Add to dashboard Cite

Objective: Few studies used all nodule burdens to specify the prognosis of multinodular goiter (MNG) following radiofrequency ablation (RFA), so this study addresses this question for MNG after completely ablating dominant nodules. Methods: The RFA indications for MNG included a total of 2-5 benign nodules with over 50% normal tissue on ultrasound, 1-3 well-defined benign dominant nodules on cytology, largest diameter ≥20 mm and/or with clinical complaints, and patient refusal or unable of surgery. A retrospective study of 185 MNG patients with completely ablated dominant nodules in a single-session RFA was conducted. The efficacy and complications were evaluated at 1, 6, 12 months and yearly thereafter. Based on retreatment risks, progressive disease (PD), stable disease (SD) and complete relief (CR) were introduced to assess all nodule load changes. PD was clarified as having new/non-target nodules newly appeared to ACR TI-RADS≥4, or new/enlarged non-target nodules ≥1 cm. Results: The initial ablation ratios of target nodules were 100% at one month. During a mean 22.38±13.75 months (range, 12-60 months), the VRR of ablated nodules was 98.25% at 24 months without regrowth. Cosmetic and symptomatic scores decreased to 1 and 0, respectively, after 48 months. 9.7% of patients (18/185) had PD and the retreatment rate was 2.2% (4/185). The complication rate was 2.7% (5/185). Conclusions: RFA provides cosmetic and symptomatic relief for an average of two years. RFA is an useful minimally invasive treatment modality for selected MNG patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Two-year prognosis of multinodular goiter following radiofrequency ablation based on all nodule burdens

Guo,

Zheng,

et al. 2024

European Thyroid Journal

View full text Add to dashboard Cite

show abstract

“…Immediate major complications were defined as RFA-related complications requiring surgical intervention or hospitalization immediately following RFA, such as tracheal and esophageal injury, and large hematoma formation, causing hemodynamic or airway compromise [ 7 20 ]. Regrowth was defined as a volume increase exceeding 50% of the smallest post-RFA volume at any given time [ 21 22 23 ]. VRR and regrowth were also dichotomized into one-year and two-year follow-up group comparisons.…”

Section: Methodsmentioning

confidence: 99%

Comparison of the Therapeutic Efficacy and Technical Outcomes between Conventional Fixed Electrodes and Adjustable Electrodes in the Radiofrequency Ablation of Benign Thyroid Nodules

Shin,

Seo,

Lee

et al. 2024

Korean J Radiol

View full text Add to dashboard Cite

Objective This study aimed to compare therapeutic efficacy and technical outcomes between adjustable electrode (AE) and conventional fixed electrode (FE) for radiofrequency ablation (RFA) of benign thyroid nodules. Materials and Methods Between 2013 and 2021, RFA was performed on histologically proven benign thyroid nodules. For the AE method, AE length ≥ 1 cm with higher power and < 1 cm with lower power were utilized for ablating feeding vessels and nodules, especially those near anatomical structures, respectively. The therapeutic efficacy (volume reduction rate [VRR], complication rate, and regrowth rate) and technical outcomes (total energy delivery, ablated volume/energy, RFA time, and ablated volume/time) of FE and AE were compared. Continuous parameters were compared using a two-sample t -test or Mann–Whitney U test, and categorical parameters were compared using a chi-squared test or Fisher’s exact test. Results A total of 182 nodules (FE: 92 vs. AE: 90) in 173 patients (mean age ± standard deviation, 47.0 ± 14.7 years; female, 90.8% [157/173]; median follow-up, 726 days [interquartile range, 441–1075 days]) were analyzed. The therapeutic efficacy was comparable, whereas technical outcomes were more favorable for AE. Both electrodes demonstrated comparable overall median VRR (FE: 92.4% vs. AE: 84.9%, P = 0.240) without immediate major complications. Overall regrowth rates were comparable between the two groups (FE: 2.2% [2/90] vs. AE: 1.1% [1/90], P > 0.99). AE demonstrated a shorter median RFA time (FE: 811 vs. AE: 627 seconds, P = 0.009). Both delivered comparable median energy (FE: 42.8 vs. AE: 29.2 kJ, P = 0.069), but AE demonstrated higher median ablated volume/energy and median ablated volume/time (FE: 0.2 vs. AE: 0.3 cc/kJ, P < 0.001; and FE: 0.7 vs. AE: 1.0 cc/min, P < 0.001, respectively). Conclusion Therapeutic efficacy between FE and AE was comparable. AE demonstrated better technical outcomes than FE in terms of RFA time, ablated volume/energy, and ablated volume/time.

show abstract

“…The cosmetic score and symptomatic score were also documented at each follow-up. As shown previously in the study of Chen et al [ 30 ], the measurement of IAR is based on the concept that the total nodule volume ( Vt ) can be divided into a vital portion ( Vv ) and an ablated ( Va ), i.e., Vt = Vv + Va . The IAR is calculated as follows: IAR = ( Va / Vt ) × 100 [ 30 , 31 ].…”

Section: Methodsmentioning

confidence: 99%

“…As shown previously in the study of Chen et al [ 30 ], the measurement of IAR is based on the concept that the total nodule volume ( Vt ) can be divided into a vital portion ( Vv ) and an ablated ( Va ), i.e., Vt = Vv + Va . The IAR is calculated as follows: IAR = ( Va / Vt ) × 100 [ 30 , 31 ]. The VRR is calculated as follows: VRR (y%) = initial volume (ml) − final volume (ml) × 100/initial volume, which is assessed by sonography.…”

Section: Methodsmentioning

confidence: 99%

Factors Influencing a Favorable Outcome for RFA of Huge Benign Thyroid Nodules: Preliminary Results and Short-Term Evaluation

Chiu,

Luo,

Chiang

et al. 2023

International Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objective. This study aimed to investigate potentially favorable factors influencing the therapeutic success of radiofrequency ablation (RFA) of huge benign thyroid nodules (BTNs) (volume >100 ml) and to evaluate the feasibility of RFA as an alternative treatment modality for patients unable or unwilling to undergo surgery. Methods. This retrospective study evaluated a total of 868 patients, of which 22 patients had huge BTNs who underwent ultrasound-guided moving shot RFA treatment between May 2017 and January 2022. The huge BTNs were categorized into two groups according to a post-RFA treatment volume reduction ratio (VRR) of >80% and <80% at 6 months. Factors influencing these huge BTNs were reviewed, analyzed, and correlated with treatment effectiveness between the two groups. Results. The factors influencing an effective VRR included huge BTNs located on the left side (OR 7.875, p = 0.03), predominant solid/spongiform nodules (OR 7.875, p = 0.03), and higher initial ablation rate (IAR) (p = 0.028). Multivariable logistic regression revealed predominant solid/spongiform nodule and the higher IAR were associated with the advanced VRR. Conclusion. RFA was effective at decreasing the volume of huge BTNs with an acceptable complication rate. The BTN characteristics correlated with a better VRR at the 6-month short-term follow-up were predominant solid/spongiform BTNs and those with the first time ablation treatment initial ablation rate. Nevertheless, regarding the higher regrowth rate of these groups of patients who may need to be treated more times, RFA can only be a feasible alternative treatment modality for patients unable or unwilling to undergo operation.

show abstract

Residual, regrowth, and new growth of radiofrequency ablation for benign thyroid nodules of different volumes: two-year follow-up results

Cited by 10 publications

References 34 publications

Two-year prognosis of multinodular goiter following radiofrequency ablation based on all nodule burdens

Two-year prognosis of multinodular goiter following radiofrequency ablation based on all nodule burdens

Comparison of the Therapeutic Efficacy and Technical Outcomes between Conventional Fixed Electrodes and Adjustable Electrodes in the Radiofrequency Ablation of Benign Thyroid Nodules

Factors Influencing a Favorable Outcome for RFA of Huge Benign Thyroid Nodules: Preliminary Results and Short-Term Evaluation

Contact Info

Product

Resources

About